Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in Clin Infect Dis

Retrieve available abstracts of 136 articles:
HTML format
Text format



Single Articles


    March 2018
  1. WALKER A, Boyce A, Geller G, Thio CL, et al
    Direct Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype.
    Clin Infect Dis. 2018 Mar 29. pii: 4956154. doi: 10.1093.
    PubMed     Text format    


  2. ROCKSTROH JK, Lacombe K, Viani RM, Orkin C, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected with Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study.
    Clin Infect Dis. 2018 Mar 16. pii: 4939381. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. BARTLETT SR, Fox P, Cabatingan H, Jaros A, et al
    Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project.
    Clin Infect Dis. 2018 Mar 12. pii: 4930770. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. KLEINSTEIN SE, Shea PR, Stamm LM, Sulkowski M, et al
    Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
    Clin Infect Dis. 2018 Mar 7. pii: 4705930. doi: 10.1093/cid/cix1051.
    PubMed     Text format     Abstract available


  5. MOGALIAN E, Stamm LM, Osinusi A, Brainard DM, et al
    Drug-Drug Interactions Studies between HCV Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted HIV Antiretroviral Regimens in Healthy Volunteers.
    Clin Infect Dis. 2018 Mar 7. pii: 4924529. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2018
  6. BAROCAS JA, Tasillo A, Eftekhari Yazdi G, Wang J, et al
    Population level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States.
    Clin Infect Dis. 2018 Feb 6. pii: 4840186. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  7. TROPPY S, Soliva S, Onofrey S, DeMaria A Jr., et al
    Geographic Disparities in Access to Syringe Services Programs Among Young Persons with Hepatitis C Virus Infection in Massachusetts.
    Clin Infect Dis. 2018 Jan 31. pii: 4831117. doi: 10.1093.
    PubMed     Text format    


    December 2017
  8. HUA S, Vigano S, Tse S, Zhengyu O, et al
    Pegylated IFN-alpha-induced NK cell activation is associated with HIV-1 DNA decline in ART-treated HIV-1/HCV co-infected patients.
    Clin Infect Dis. 2017 Dec 20. pii: 4767848. doi: 10.1093/cid/cix1111.
    PubMed     Text format     Abstract available


  9. YOUNOSSI ZM, Stepanova M, Asselah T, Foster G, et al
    Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes.
    Clin Infect Dis. 2017 Dec 20. pii: 4766885. doi: 10.1093/cid/cix1106.
    PubMed     Text format     Abstract available


  10. RICKLES M, Rebeiro PF, Sizemore L, Juarez P, et al
    Tennessee's In-State Vulnerability Assessment for a 'Rapid Dissemination of HIV or HCV Infection' Event Utilizing Data about the Opioid Epidemic.
    Clin Infect Dis. 2017 Dec 7. pii: 4706246. doi: 10.1093/cid/cix1079.
    PubMed     Text format     Abstract available


  11. KAPADIA SN, Jeng PJ, Schackman BR, Bao Y, et al
    State Medicaid hepatitis C treatment eligibility criteria and use of direct acting antivirals.
    Clin Infect Dis. 2017 Dec 1. pii: 4682615. doi: 10.1093/cid/cix1062.
    PubMed     Text format     Abstract available


    November 2017
  12. BOEREKAMPS A, Newsum AM, Smit C, Arends JE, et al
    High treatment uptake in HIV/HCV-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands.
    Clin Infect Dis. 2017 Nov 23. pii: 4654728. doi: 10.1093/cid/cix1004.
    PubMed     Text format     Abstract available


  13. ROCKSTROH JK
    Is HCV elimination in well-defined patient groups possible?
    Clin Infect Dis. 2017 Nov 23. pii: 4654730. doi: 10.1093/cid/cix1010.
    PubMed     Text format    


  14. BOEREKAMPS A, Van den Berk GE, Fanny LN, Leyten EM, et al
    Declining HCV incidence in Dutch HIV positive men who have sex with men after unrestricted access to HCV therapy.
    Clin Infect Dis. 2017 Nov 23. pii: 4654729. doi: 10.1093/cid/cix1007.
    PubMed     Text format     Abstract available


  15. BEDIMO RJ, Adams-Huet B, Poindexter J, Brown G, et al
    The Differential Effects of HIV and HCV on Bone Micro-Architecture and Fracture risk.
    Clin Infect Dis. 2017 Nov 14. doi: 10.1093/cid/cix1011.
    PubMed     Text format     Abstract available


    October 2017
  16. DE LEDINGHEN V, Laforest C, Hezode C, Pol S, et al
    Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.
    Clin Infect Dis. 2017 Oct 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. YAYA I, Costa M, Marcellin F, Miailhes P, et al
    Gender, alcohol use and fibrosis in HIV-HCV co-infected individuals.
    Clin Infect Dis. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


  18. PARR JB, Lodge EK, Holzmayer V, Pepin J, et al
    An Efficient, Large-Scale Survey of Hepatitis C Viremia in the Democratic Republic of the Congo Using Dried Blood Spots.
    Clin Infect Dis. 2017 Oct 18. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  19. BUTT AA, Yan P, Simon TG, Abou-Samra AB, et al
    Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
    Clin Infect Dis. 2017;65:1006-1011.
    PubMed     Text format     Abstract available


  20. HASHEM M, Jhaveri R, Saleh DA, Sharaf SA, et al
    Spontaneous Viral Load Decline and Subsequent Clearance of Chronic Hepatitis C Virus in Postpartum Women Correlates With Favorable Interleukin-28B Gene Allele.
    Clin Infect Dis. 2017;65:999-1005.
    PubMed     Text format     Abstract available


  21. ASSOUMOU SA, Tasillo A, Leff JA, Schackman BR, et al
    The cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. CHHATWAL J
    Hepatitis C screening: From modeling to public health policy.
    Clin Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format    


  23. LIU CH, Chen YS, Wang SS, Liu CJ, et al
    Sofosbuvir-based interferon-free direct acting antiviral regimens for heart transplant recipients with chronic hepatitis C virus infection.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format     Abstract available


  24. WEINBERG EM, Reddy KR
    Let's Make a Deal: Shortening the solid organ transplant waiting time in exchange for transmitting and treating Hepatitis C infection in the era of safe and effective DAAs.
    Clin Infect Dis. 2017 Sep 4. doi: 10.1093.
    PubMed     Text format    


    August 2017
  25. ESMAEILI A, Mirzazadeh A, Morris MD, Hajarizadeh B, et al
    The effect of female sex on hepatitis C incidence among people who inject drugs: results from the international multi-cohort InC3 Collaborative.
    Clin Infect Dis. 2017 Aug 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. ABRAHAM GM, Spooner LM
    Citius Altius Fortius: The New Paradigm In The Treatment Of Chronic Hepatitis C Disease.
    Clin Infect Dis. 2017 Aug 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. KOUAME GM, Boyd A, Moh R, Badje A, et al
    Higher mortality despite early ART in HIV and hepatitis B virus coinfected patients with high HBV replication.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. WANG H, Wan Z, Xu R, Guan Y, et al
    A Novel Human Pegivirus HPgV-2 (HHpgV-1) is Tightly Associated with HCV Infection and HCV/HIV-1 Co-Infection.
    Clin Infect Dis. 2017 Aug 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. KELLY EM, Dodge JL, Bacchetti P, Sarkar M, et al
    Moderate Alcohol use is not Associated with Fibrosis Progression in HIV/HCV Co-Infected Women: A Prospective Cohort Study.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. LO RE V 3RD
    Is Moderate Alcohol Consumption Safe for HIV/Hepatitis C Virus-Coinfected Women?
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format    


  31. BYRNE DD, Tate JP, Forde KA, Lim JK, et al
    Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.
    Clin Infect Dis. 2017 Aug 16. doi: 10.1093.
    PubMed     Text format     Abstract available


    July 2017
  32. SARKAR M, Dodge JL, Greenblatt RM, Kuniholm MH, et al
    Reproductive Aging and Hepatic Fibrosis Progression in HIV/Hepatitis C Virus Co-Infected Women.
    Clin Infect Dis. 2017 Jul 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  33. POWDERLY WG, Naggie S, Kim AY, Vargas HE, et al
    IDSA/AASLD response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.
    Clin Infect Dis. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format    


    June 2017
  34. CHI H, Wong D, Peng J, Cao J, et al
    Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation.
    Clin Infect Dis. 2017 Jun 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2017
  35. KIM AY
    The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.
    Clin Infect Dis. 2017 May 27. doi: 10.1093.
    PubMed     Text format    


  36. FELD JJ, Ramji A, Shafran SD, Willems B, et al
    Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.
    Clin Infect Dis. 2017 May 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  37. ZUCMAN D, Farfour E, Mazaux L, Hillaire S, et al
    How to face the outbreak of viral hepatitis A in men-who-have-sex-with-men in France without vaccines?
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  38. BOSCHI C, Colson P, Tissot-Dupont H, Bernit E, et al
    Hepatitis C virus relapse 78 weeks after completion of successful direct acting therapy.
    Clin Infect Dis. 2017 May 16. doi: 10.1093.
    PubMed     Text format    


  39. MOON J, Hyland RH, Zhang F, Brainard DM, et al
    Efficacy and safety of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease.
    Clin Infect Dis. 2017 May 13. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  40. ROSENBERG ES, Hall EW, Sullivan PS, Sanchez TH, et al
    Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010.
    Clin Infect Dis. 2017 Apr 26. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. OZARAS R, Balkan II, Yemisen M, Mete B, et al
    Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  42. BUTT AA, Yan P, Chew KW, Currier J, et al
    Risk of Acute Myocardial Infarction Among HCV+ and HCV- Men at Various Lipid Levels: Results from ERCHIVES.
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. TIEN PC
    HCV-associated Alterations in Lipid and Lipoprotein levels: Helpful or Harmful to the Heart?
    Clin Infect Dis. 2017 Apr 24. doi: 10.1093.
    PubMed     Text format    


  44. CANARY L, Hariri S, Campbell C, Young R, et al
    Geographic disparities in access to syringe services programs among young people with hepatitis C virus infection in the U.S.
    Clin Infect Dis. 2017 Apr 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. MORRIS MD, Shiboski S, Bruneau J, Hahn JA, et al
    Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Clin Infect Dis. 2017;64:860-869.
    PubMed     Text format     Abstract available


  46. NOSKA AJ, Belperio PS, Loomis TP, O'Toole TP, et al
    Prevalence of HIV, HCV and HBV among Homeless and Non-homeless United States Veterans.
    Clin Infect Dis. 2017 Apr 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  47. WYLES D, Brau N, Kottilil S, Daar ES, et al
    Sofosbuvir and Velpatasvir for the Treatment of HCV in Patients Coinfected with HIV-1: an Open-Label, Phase 3 Study.
    Clin Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  48. BUTT AA, Ren Y, Lo Re V 3rd, Taddei T, et al
    Comparing Child-Pugh, MELD and FIB-4 to Predict Clinical Outcomes in HCV-Infected Persons: Results from ERCHIVES.
    Clin Infect Dis. 2017 Mar 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. CEPEDA JA, Thomas DL, Astemborski J, Sulkowski MS, et al
    Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. HEZODE C, Fourati S, Chevaliez S, Scoazec G, et al
    Sofosbuvir-Daclatasvir-Simeprevir plus Ribavirin in Direct-Acting Antiviral-Experienced Hepatitis C Patients.
    Clin Infect Dis. 2017 Mar 10. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  51. NAGGIE S, Marks KM, Hughes M, Fierer DS, et al
    Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
    Clin Infect Dis. 2017 Feb 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  52. ANDERSON ES, Galbraith JW, Deering LJ, Pfeil SK, et al
    Continuum of Care for HCV Among Patients Diagnosed in the Emergency Department Setting.
    Clin Infect Dis. 2017 Feb 16. doi: 10.1093.
    PubMed     Text format    


  53. LO RE V
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2017;64:498-500.
    PubMed     Text format    


  54. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C Infection and the Risk of Non-Liver-Related Morbidity and Mortality in HIV-Infected Persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017;64:490-497.
    PubMed     Text format    


  55. BLOCK TM, Locarnini S, McMahon BJ, Rehermann B, et al
    Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  56. YOUNG J, Rossi C, Gill J, Walmsley S, et al
    Risk factors for hepatitis C virus reinfection after sustained virologic response in patients co-infected with HIV.
    Clin Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  57. BHATTACHARYA D, Belperio PS, Shahoumian TA, Loomis TP, et al
    Effectiveness of All-Oral Antiviral Regimens in 996 Genotype 1 HIV/HCV Coinfected Patients Treated in Routine Practice.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  58. BURTON MJ, Naggie S
    Real World Effectiveness of DAA Therapies in HIV/HCV Co-Infection: 996 Veterans Can't Be Wrong.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  59. BEGUELIN C, Friolet N, Moradpour D, Sahli R, et al
    Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2017 Feb 11. doi: 10.1093.
    PubMed     Text format    


  60. ANDREONI M, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  61. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin-18 in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Coinfection Versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  62. VINIKOOR MJ, Sinkala E, Chilengi R, Mulenga L, et al
    Impact of antiretroviral therapy on liver fibrosis among HIV-infected adults with and without HBV coinfection in Zambia.
    Clin Infect Dis. 2017 Feb 4. doi: 10.1093.
    PubMed     Text format    


    January 2017
  63. RIVERO-JUAREZ A, Frias M, Lopez-Lopez P, Risalde ML, et al
    Hepatitis E virus infection in anti-HEV IgG-carryinfing patients after successful HCV treatment: reactivation or reinfection?
    Clin Infect Dis. 2017 Jan 11. pii: cix004. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2016
  64. MASSIMO A, Teti E, Antinori A, Milazzoi L, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.
    Clin Infect Dis. 2016 Dec 22. pii: ciw846. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. LO RE V 3RD
    Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  66. KOVARI H, Rauch A, Kouyos R, Rougemont M, et al
    Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  67. FORD MM, Johnson N, Desai P, Rude E, et al
    From Care to Cure: Demonstrating a Model of Clinical Patient Navigation for Hepatitis C Care and Treatment in High-Need Patients.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  68. VEENHUIS RT, Astemborski J, Chattergoon MA, Greenwood P, et al
    Systemic Elevation of Proinflammatory Interleukin 18 in HIV/HCV Coinfection versus HIV or HCV Monoinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    November 2016
  69. LIEVELD FI, Arends JE, Amelung L, Dijk E, et al
    Overcoming Outpatient Loss to Follow-up as a Barrier to Efficiently Instituting Hepatitis B Liver-related Care.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  70. FOSTER AL, Gaisa MM, Hijdra RM, Turner SS, et al
    Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men.
    Clin Infect Dis. 2016 Nov 9. pii: ciw740. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. BAROCAS JA, Linas BP
    Decision Science at Work: The Case of Hepatitis C Virus Postexposure Prophylaxis.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    October 2016
  72. SARRAZIN C, Isakov V, Svarovskaia E, Hedskog C, et al
    Late relapse versus HCV reinfection in patients with sustained virologic response after sofosbuvir-based therapies.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    September 2016
  73. NAGGIE S, Holland D, Sulkowski MS, Thomas DL, et al
    HCV post-exposure prophylaxis in the healthcare worker: Why DAAs don't change a thing.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  74. MOORE MS, Ivanina E, Bornschlegel K, Qiao B, et al
    Hepatocellular Carcinoma and Viral Hepatitis in New York City.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  75. GREBELY J, Dore GJ, Zeuzem S, Aspinall RJ, et al
    Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of Phase 3 ASTRAL trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  76. GREBELY J, Mauss S, Brown A, Bronowicki JP, et al
    Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  77. INGILIZ P, Christensen S, Kimhofer T, Hueppe D, et al
    Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals - Results from the German hepatitis C cohort (GECCO-01).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  78. KLEVENS RM, Canary L, Huang X, Denniston MM, et al
    The Burden of Hepatitis C Infection-Related Liver Fibrosis in the United States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  79. KLEIN MB, Althoff KN, Jing Y, Lau B, et al
    Risk of endstage liver disease in HIV-viral hepatitis co-infected persons in North America from the early to modern antiretroviral therapy eras.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  80. ABRAVANEL F, Metivier S, Chauveau M, Peron JM, et al
    Transmission of HCV NS5A inhibitor-resistant variants among HIV-infected men who have sex with men.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  81. KAMSTRA R, Azoulay L, Steele R, Klein MB, et al
    Hospitalizations in immigrants and non-immigrants diagnosed with chronic hepatitis C infection in Quebec.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  82. SPRADLING PR, Xing J, Rupp LB, Moorman AC, et al
    Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  83. MCMAHON BJ
    Sliding Down the Cascade of Care for Chronic Hepatitis B Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  84. SULKOWSKI MS, Chuang WL, Kao JH, Yang JC, et al
    No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated with Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  85. YOUNOSSI ZM, Stepanova M, Sulkowski M, Foster GR, et al
    Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and 3 Clinical Trials.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available



  86. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  87. WYLES DL, Sulkowski MS, Dieterich D
    Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Clin Infect Dis. 2016;63 Suppl 1:S3-S11.
    PubMed     Text format     Abstract available


  88. MACBRAYNE CE, Kiser JJ
    Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    Clin Infect Dis. 2016;63 Suppl 1:S12-23.
    PubMed     Text format     Abstract available


  89. ROWAN SE, Rogers M, Bayer J, Smith L, et al
    Treatment of HCV in HIV coinfected individuals in real world clinical settings: results from two large HIV care clinics.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  90. AL-KINDI SG, Zidar DA, McComsey GA, Longenecker CT, et al
    Gender differences in statin prescription rate among patients living with HIV and HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format    


    June 2016
  91. FEDELI U, Schievano E
    Mortality waves related to Hepatitis C virus infection: multiple causes of death data from the US and Northern Italy compared.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  92. FELD JJ, Maan R, Zeuzem S, Kuo A, et al
    Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  93. SOGNI P, Gilbert C, Lacombe K, Piroth L, et al
    All-oral DAA regimens in HIV-HCV coinfected cirrhotic patients are efficient and safe. Real-life results from the prospective ANRS CO13 - HEPAVIH cohort.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  94. GJAERDE LI, Shepherd L, Jablonowska E, Lazzarin A, et al
    Trends in incidences and risk factors for hepatocellular carcinoma and other liver events in HIV and hepatitis C virus co-infected individuals from 2001 to 2014: a multi-cohort study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  95. HEDENSTIERNA M, Nangarhari A, Weiland O, Aleman S, et al
    Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  96. WILSON EM, Tang L, Kottilil S
    Eradication Strategies for Chronic Hepatitis B Infection.
    Clin Infect Dis. 2016;62 Suppl 4:S318-25.
    PubMed     Text format     Abstract available


  97. TRAN TT
    Hepatitis B in Pregnancy.
    Clin Infect Dis. 2016;62 Suppl 4:S314-7.
    PubMed     Text format     Abstract available


  98. GONZALEZ SA, Perrillo RP
    Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.
    Clin Infect Dis. 2016;62 Suppl 4:S306-13.
    PubMed     Text format     Abstract available


  99. WONG GL, Wong VW, Chan HL
    Virus and Host Testing to Manage Chronic Hepatitis B.
    Clin Infect Dis. 2016;62 Suppl 4:S298-305.
    PubMed     Text format     Abstract available


  100. SHANKAR H, Blanas D, Bichoupan K, Ndiaye D, et al
    A Novel Collaborative Community-Based Hepatitis B Screening and Linkage to Care Program for African Immigrants.
    Clin Infect Dis. 2016;62 Suppl 4:S289-97.
    PubMed     Text format     Abstract available


  101. DANDRI M, Petersen J
    Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.
    Clin Infect Dis. 2016;62 Suppl 4:S281-8.
    PubMed     Text format     Abstract available


    May 2016
  102. COOPER C, Naggie S, Saag M, Yang JC, et al
    Successful Retreatment of HCV in Patients Coinfected with HIV Who Failed 12 Weeks of Ledipasvir/Sofosbuvir.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  103. KELLY EM, Dodge JL, Sarkar M, French AL, et al
    Marijuana Use is not Associated with Progression to Advanced Liver Fibrosis in HIV/HCV Coinfected Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  104. SOLLIMA S, D'Avolio A, Cattaneo D, Micheli V, et al
    Darunavir-based antiretroviral therapy may affect the efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in HCV/HIV-1 coinfected patients.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  105. CLEMENT ME, Park LP, Navar AM, Okeke NL, et al
    Statin Utilization and Recommendations Among HIV and HCV-Infected Veterans: A Cohort Study.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    April 2016
  106. KANWAL F, Kramer JR, El-Serag HB, Frayne S, et al
    Race and gender differences in the use of direct acting antiviral agents for HCV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  107. NICOLAS D, Esteve A, Cuadros A, Campbell CN, et al
    Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  108. RAMSAY I, Gorton RL, Patel M, Workman S, et al
    Transmission of Hepatitis B core Antibody and Galactomannan Enzyme Immunoassay positivity via immunoglobulin products: a comprehensive analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  109. SHAFRAN SD
    Reply to Menard et al.
    Clin Infect Dis. 2016;62:949-50.
    PubMed     Text format    


    March 2016
  110. LUETKEMEYER AF, McDonald C, Ramgopal M, Noviello S, et al
    12 Weeks of Daclatasvir in Combination with Sofosbuvir for HIV-HCV Coinfection (ALLY-2 study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  111. RIVERO-JUAREZ A, Frias M, Rodriguez-Cano D, Cuenca-Lopez F, et al
    Isolation of Hepatitis E virus from breast milk during acute infection.
    Clin Infect Dis. 2016.
    PubMed     Text format    


  112. TOSTI ME, Alfonsi V, Lacorte E, Mele A, et al
    Acute hepatitis B after the implementation of universal vaccination in Italy: results from a 22-years surveillance (1993-2014).
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  113. LY KN, Hughes EM, Jiles RB, Holmberg SD, et al
    Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  114. DEL BELLO D, Cha A, Sorbera M, Bichoupan K, et al
    Real-world Sustained Virologic Response Rates of Sofosbuvir-containing Regimens in Patients Coinfected with Hepatitis C and HIV.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  115. HSIEH YH, Rothman RE, Laeyendecker OB, Kelen GD, et al
    Evaluation of The CDC Recommendations for HCV Testing in an Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  116. LYONS MS, Kunnathur VA, Rouster SD, Hart KW, et al
    Prevalence of Diagnosed and Undiagnosed Hepatitis C in a Midwestern Urban Emergency Department.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  117. MARTIN NK, Thornton A, Hickman M, Sabin C, et al
    Can HCV direct-acting antiviral treatment as prevention reverse the HCV epidemic amongst men who have sex with men in the UK - epidemiological and modelling insights.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  118. JONAS MC, Rodriguez CV, Redd J, Sloane DA, et al
    Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  119. HARRINGTON PR, Fleischer R, Connelly SM, Lewis LL, et al
    Reply to Merli et al.
    Clin Infect Dis. 2016;62:528-9.
    PubMed     Text format    


  120. VERMEHREN J, Maasoumy B, Maan R, Cloherty G, et al
    Applicability of HCV RNA viral load thresholds for 8-week treatments in patients with chronic hepatitis C genotype 1 infection.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


    January 2016
  121. KUNCIO DE, Newbern EC, Johnson CC, Viner KM, et al
    Failure to Test and Identify Perinatally Infected Children Born to Hepatitis C-Positive Women.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  122. SIMMONS B, Saleem J, Hill A, Riley RD, et al
    Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
    Clin Infect Dis. 2016.
    PubMed     Text format     Abstract available


  123. SAEED S, Strumpf EC, Walmsley S, Rollet-Kurhajec K, et al
    How generalizable are the results from trials of Direct Antiviral Agents to people coinfected with HIV/Hepatitis C virus in the real world?
    Clin Infect Dis. 2016 Jan 6. pii: civ1222.
    PubMed     Text format     Abstract available


  124. MARTINELLO M, Dore GJ
    HCV direct-acting antivirals in the "real world": Efficacy comparable to clinical trials.
    Clin Infect Dis. 2016 Jan 6. pii: civ1227.
    PubMed     Text format    


  125. MENARD A, Colson P, Catherine D, Isabelle R, et al
    First real life evidence of new direct-acting antivirals (DAA) in co-infected HIV HCV patients: better than ever.
    Clin Infect Dis. 2016 Jan 5. pii: civ1215.
    PubMed     Text format    


  126. KHATRI A, Dutta S, Wang H, Podsadecki T, et al
    Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Clin Infect Dis. 2016 Jan 5. pii: civ1213.
    PubMed     Text format     Abstract available


  127. STOCKDALE AJ, Geretti AM
    Reply to Boyd and Lacombe.
    Clin Infect Dis. 2016;62:130-1.
    PubMed     Text format    


  128. KESHTKAR-JAHROMI M, Rassaei N, Bruno MA, Maneval ML, et al
    Photo Quiz. A 59-Year-Old Man With Multiple Liver Lesions, Rash, and Uveitis.
    Clin Infect Dis. 2016;62:82-3.
    PubMed     Text format    


    November 2015
  129. DURHAM DP, Skrip LA, Bruce RD, Vilarinho S, et al
    The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  130. DONNELLY JP, Franco R, Wang HE, Galbraith JW, et al
    Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


  131. HONER ZU SIEDERDISSEN C, Maasoumy B, Marra F, Deterding K, et al
    Drug-drug interactions with novel all oral interferon free antiviral agents in a large real-world cohort.
    Clin Infect Dis. 2015.
    PubMed     Text format     Abstract available


    September 2015
  132. BOYD A, Lacombe K
    More long-term assessment of transient elastography is needed for HIV-HBV co-infected patients undergoing treatment with tenofovir.
    Clin Infect Dis. 2015.
    PubMed     Text format    


  133. BALAGOPAL A, Thomas DL
    Editorial Commentary: Who is "Special" Now?
    Clin Infect Dis. 2015;61:826-8.
    PubMed     Text format    


    August 2015
  134. SIDHARTHAN S, Kohli A, Kottilil S
    Reply to Harrington et al.
    Clin Infect Dis. 2015;61:667-8.
    PubMed     Text format    


    July 2015
  135. STARK JE
    Potential for a Significant Interaction Between Clopidogrel and Dasabuvir.
    Clin Infect Dis. 2015;61:134-5.
    PubMed     Text format    


    November 2014
  136. ABRAHAM AG, Althoff KN, Jing Y, Estrella MM, et al
    End Stage Renal Disease Among HIV-Infected Adults in North America.
    Clin Infect Dis. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: